Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon 10 vs 15 cm^2 Patch in AD with Decline
NCT00506415Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Primary completion
- May 2011
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 7
01
Overview
A Phase 3 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Jun 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00506415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506415.